Enhanced Therapeutic Potential of Hybrid Exosomes Loaded with Paclitaxel for Cancer Therapy
International Journal of Molecular Sciences · 25.03.2024 · 25 (7) · 3645
DOI: 10.3390/ijms25073645 ↗Kurz gefasst
Fachartikel in der Zeitschrift International Journal of Molecular Sciences, online erschienen am 25.03.2024. Verfasst von Xuan Wang und 8 weiteren Autor:innen. Beteiligte Einrichtung: National Engineering Laboratory for AIDS Vaccine, School of Life Sciences, Jilin University, Changchun 130012, China. Hauptthemen laut MEDLINE: Exosomes, Neoplasms. Die Arbeit wurde bisher 58-mal zitiert (Crossref) und nennt 29 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: National Natural Science Foundation of China.
Abstract (Originalsprache)
The advancement of exosome studies has positioned engineered exosomes as crucial biomaterials for the development of advanced drug delivery systems. This study focuses on developing a hybrid exosome system by fusing mesenchymal stem cells (MSCs) exosomes with folate-targeted liposomes. The aim was to improve the drug loading capacity and target modification of exosome nanocarriers for delivering the first-line chemotherapy drug paclitaxel (PTX) and its effectiveness was assessed through cellular uptake studies to evaluate its ability to deliver drugs to tumor cells in vitro. Additionally, in vivo experiments were conducted using a CT26 tumor-bearing mouse model to assess the therapeutic efficacy of hybrid exosomes loaded with PTX (ELP). Cellular uptake studies demonstrated that ELP exhibited superior drug delivery capabilities to tumor cells in vitro. Moreover, in vivo experiments revealed that ELP significantly suppressed tumor growth in the CT26 tumor-bearing mouse model. Notably, for the first time, we examined the tumor microenvironment following intratumoral administration of ELP. We observed that ELP treatment activated CD4+ and CD8+ T cells, reduced the expression of M2 type tumor-associated macrophages (TAMs), polarized TAMs towards the M1 type, and decreased regulatory T cells (Tregs). Our research highlights the considerable therapeutic efficacy of ELP and its promising potential for future application in cancer therapy. The development of hybrid exosomes presents an innovative approach to enhance drug delivery and modulate the tumor microenvironment, offering exciting prospects for effective cancer treatment strategies.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- National Engineering Laboratory for AIDS Vaccine, School of Life Sciences, Jilin University, Changchun 130012, China.
- Key Laboratory for Molecular Enzymology and Engineering of Ministry of Education, School of Life Sciences, Jilin University, Changchun 130012, China.
Förderung
- National Natural Science Foundation of China
Zitieren
APA
Wang, X., Li, D., Li, G., Chen, J., Yang, Y., Bian, L., Zhou, J., Wu, Y., & Chen, Y. (2024). Enhanced Therapeutic Potential of Hybrid Exosomes Loaded with Paclitaxel for Cancer Therapy. International Journal of Molecular Sciences, 25(7), 3645. https://doi.org/10.3390/ijms25073645
Vancouver
Wang X, Li D, Li G, Chen J, Yang Y, Bian L, et al. Enhanced Therapeutic Potential of Hybrid Exosomes Loaded with Paclitaxel for Cancer Therapy. International Journal of Molecular Sciences. 2024;25(7):3645. doi:10.3390/ijms25073645
BibTeX
@article{Wang2024,
author = {Wang, Xuan and Li, Dongdong and Li, Gaotian and Chen, Jinda and Yang, Yi and Bian, Lijun and Zhou, Jingying and Wu, Yongge and Chen, Yan},
title = {Enhanced Therapeutic Potential of Hybrid Exosomes Loaded with Paclitaxel for Cancer Therapy},
journal = {International Journal of Molecular Sciences},
year = {2024},
volume = {25},
number = {7},
pages = {3645},
doi = {10.3390/ijms25073645}
}
EUVIMED